ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,13912
-0,62%
Bitcoin
69.138,45
0,92%
Brent Oil
82,165
0,23%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. 23andMe Holding Company (ME)

  7. 23andMe Holding Company (ME) Notícias

ME

23andMe (ME)

23andMe Holding Company
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ME
DataHoraFonteTítuloCódigoCompanhia
24/05/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ME23andMe Holding Company
23/05/202418:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ME23andMe Holding Company
23/05/202417:05GlobeNewswire Inc.23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
14/05/202408:00GlobeNewswire Inc.Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsNASDAQ:ME23andMe Holding Company
09/05/202417:50GlobeNewswire Inc.23andMe to Report Q4 and Full Year FY2024 Financial ResultsNASDAQ:ME23andMe Holding Company
30/04/202412:00Business WirePotter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach CaseNASDAQ:ME23andMe Holding Company
24/04/202417:05GlobeNewswire Inc.23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:ME23andMe Holding Company
18/04/202409:00GlobeNewswire Inc.23andMe announces CEO’s intention to pursue a potential take-privateNASDAQ:ME23andMe Holding Company
05/04/202417:05GlobeNewswire Inc.23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
20/03/202408:30GlobeNewswire Inc.23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6NASDAQ:ME23andMe Holding Company
19/03/202409:00GlobeNewswire Inc.23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoNASDAQ:ME23andMe Holding Company
06/03/202409:30GlobeNewswire Inc.23andMe Launches New Genetic Reports on Common Forms of CancerNASDAQ:ME23andMe Holding Company
05/03/202418:30GlobeNewswire Inc.23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ME23andMe Holding Company
07/02/202418:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ME23andMe Holding Company
07/02/202418:01GlobeNewswire Inc.23andMe Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
06/02/202409:00Business WireMoneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc.NASDAQ:ME23andMe Holding Company
31/01/202400:12GlobeNewswire Inc.23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernayNASDAQ:ME23andMe Holding Company
30/01/202419:00Business WireNighthawk Gold Obtains Final Court Order for the Proposed ArrangementNASDAQ:ME23andMe Holding Company
24/01/202418:05GlobeNewswire Inc.23andMe to Report FY2024 Third Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
22/01/202410:00Business WireMoneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo BoardNASDAQ:ME23andMe Holding Company
19/12/202310:00GlobeNewswire Inc.23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohortsNASDAQ:ME23andMe Holding Company
01/12/202318:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ME23andMe Holding Company
28/11/202309:15Business WireNighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development CompanyNASDAQ:ME23andMe Holding Company
08/11/202318:05GlobeNewswire Inc.23andMe Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:ME23andMe Holding Company
07/11/202310:00GlobeNewswire Inc.23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health MembershipNASDAQ:ME23andMe Holding Company
06/11/202310:00GlobeNewswire Inc.23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1NASDAQ:ME23andMe Holding Company
31/10/202309:00GlobeNewswire Inc.23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health DataNASDAQ:ME23andMe Holding Company
30/10/202309:00GlobeNewswire Inc.23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSKNASDAQ:ME23andMe Holding Company
25/10/202317:05GlobeNewswire Inc.23andMe to Report FY2024 Second Quarter Financial ResultsNASDAQ:ME23andMe Holding Company
27/09/202317:05GlobeNewswire Inc.23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual MeetingNASDAQ:ME23andMe Holding Company
 Apresentando as notícias mais relevantes sobre:NASDAQ:ME

Seu Histórico Recente

BOV
SGPS3
SPRINGS ON
BOV
COGN3
COGNA ON
BOV
PSVM11
PORTO SUDESTE
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados